A large observational study involving 1412 propensity score-matched patients undergoing anthracycline therapy demonstrated that SGLT2 inhibitor use was associated with a significant reduction in the incidence of new-onset heart failure and arrhythmias over a two-year follow-up period. This evidence concerns the gene SLC5A2 and heart failure.